Drugs / HS-20093
Regulatory milestones approvals, filings & regulatory actions · 2 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Filed bone osteosarcoma 1 milestone | |||||
| Filed | China (NMPA) | — | bone osteosarcoma | 2026-09-24 | “用于治疗≥12周岁经既往至少二线治疗失败的骨肉瘤患者的上市许可申请获中国国家药品监督管理局(NMPA)受理” hansoh.cn ↗ |
| Filed small cell lung carcinoma 1 milestone | |||||
| Filed | China (NMPA) | — | small cell lung carcinoma | 2026-09-02 | “HS-20093（risvutatug rezetecan, or Ris-Rez）for injection was been accepted by the National Medical Products Administration (the “NMPA”） of China on September 2, 2026” hspharm.com ↗ “HS-20093（Risvutatug Rezetecan）用于治疗既往含铂治疗失败的小细胞肺癌（SCLC）成人患者的上市许可申请获中国国家药品监督管理局(NMPA)受理” hansoh.cn ↗ |
Trials 24
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 111 trials | ||||||
| Phase 1 | NCT07462923 | Jan → Dec 2026 expected | adenocarcinoma | Hansoh BioMedical R&D Company | Recruiting | No outcome recorded |
| Phase 1 | NCT07186452 | Sep 2025 → Jul 2026 overdue | cancer | Hansoh BioMedical R&D Company | Recruiting | No outcome recorded |
| Phase 1 | NCT07115446 | Aug 2025 → Dec 2027 expected | prostate cancer | Hansoh BioMedical R&D Company | Recruiting | No outcome recorded |
| Phase 1 | NCT07063407 | Jul 2025 → Apr 2026 overdue | small cell lung carcinoma | Shanghai Hansoh Biomedical Co., Ltd | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT06963502 | May 2025 → Dec 2028 expected | colorectal cancer, non-small cell lung carcinoma | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT06769425 | May 2025 → May 2026 overdue | female breast carcinoma, gastric cancer, ovarian cancer, prostate cancer +1 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1 | NCT06699576 | Dec 2024 → Dec 2026 expected | osteosarcoma, soft tissue sarcoma | Hansoh BioMedical R&D Company | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT06621563 | Dec 2024 → Mar 2026 overdue | colorectal cancer, non-small cell lung carcinoma | Hansoh BioMedical R&D Company | Recruiting | No outcome recorded |
| Phase 1 | NCT06825624 | Oct 2024 → Oct 2026 expected | colorectal cancer | Hansoh BioMedical R&D Company | Recruiting | No outcome recorded |
| Phase 1 | NCT06332170 | Apr 2024 → May 2026 overdue | neoplastic disease or syndrome | Hansoh BioMedical R&D Company | Recruiting | No outcome recorded |
| Phase 1 | NCT05276609 | Nov 2021 → Dec 2023 | neoplasm | Shanghai Hansoh Biomedical Co., Ltd | Unknown | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT07736612 | Aug 2026 → Aug 2028 expected | malignant pancreatic neoplasm | Zhejiang University | Not yet recruiting | No outcome recorded |
| Phase 27 trials | ||||||
| Phase 2 | NCT07824882 | Sep 2026 → Mar 2028 expected | non-small cell lung carcinoma | Hansoh BioMedical R&D Company | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07230106 | Dec 2025 → Dec 2028 expected | prostate cancer | Jiangsu HengRui Medicine Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT06052423 | Nov 2024 → Jun 2025 | small cell lung carcinoma | Hansoh BioMedical R&D Company | Withdrawn | No outcome recorded Stop: Business |
| Phase 2 | NCT06112704 | Feb 2024 → Jul 2026 overdue | neoplasm | Hansoh BioMedical R&D Company | Recruiting | No outcome recorded |
| Phase 2 | NCT06001255 | Jan → Dec 2024 overdue | castration-resistant prostate carcinoma | Hansoh BioMedical R&D Company | Recruiting | No outcome recorded |
| Phase 2 | NCT06007729 | Dec 2023 → Dec 2025 overdue | head and neck squamous cell carcinoma | Hansoh BioMedical R&D Company | Recruiting | No outcome recorded |
| Phase 2 | NCT05830123 | Jun 2023 → Dec 2025 overdue | osteosarcoma | Hansoh BioMedical R&D Company | Recruiting | No outcome recorded |
| Phase 35 trials · 1 met primary | ||||||
| Phase 3 | NCT07621601 | Jul 2026 → Dec 2030 expected | esophageal squamous cell carcinoma | Hansoh BioMedical R&D Company | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07464327 | Mar 2026 → Dec 2028 expected | non-small cell lung carcinoma | Hansoh BioMedical R&D Company | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06935409 | Apr 2025 → Aug 2026 overdue | osteosarcoma | Hansoh BioMedical R&D Company | Active not recruiting | Met primary |
| Phase 3 | NCT06526624 | Sep 2024 → Nov 2027 expected | small cell lung carcinoma | Hansoh BioMedical R&D Company | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06498479 | Jul 2024 → Sep 2026 overdue | small cell lung carcinoma | Hansoh BioMedical R&D Company | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 41
| Date | Issuer | Release |
|---|---|---|
| 2026-09-24 | Hansoh BioMedical R&D Company | Regulatory 翰森制药 | 瑞康立伏妥塔单抗治疗骨肉瘤上市许可申请获国家药品监督管理局受理 hansoh.cn ↗
2026年9月24日，翰森制药集团有限公司（翰森制药，03692. HK）宣布，公司自主研发的注射用瑞康立伏妥塔单抗（HS-20093）用于治疗≥12周岁经既往至少二线治疗失败的骨肉瘤患者的上市许可申请获中国国家药品监督管理局(NMPA)受理，受理号为CXSS2600155，该适应症此前已于2026年9月14日被NMPA纳入优先审评审批程序. |
| 2026-09-13 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Results 2026 WCLC | HANSOH PHARMA ANNOUNCES INTERIM RESULTS FROM PHASE 3 ARTEMIS-008 STUDY OF RISVUTATUG REZETECAN (HS-20093) IN PATIENTS WITH RELAPSED SMALL CELL LUNG CANCER hspharm.com ↗
At the prespecified interim analysis, the study met its primary endpoint of OS, demonstrating a statistically significant and clinically meaningful improvement in survival. |
| 2026-09-13 | Hansoh BioMedical R&D Company | Results WCLC 2026 | 翰森制药公布瑞康立伏妥塔单抗（HS-20093）用于复发性小细胞肺癌患者Ⅲ期ARTEMIS-008研究期中数据 hansoh.cn ↗
此次WCLC 2026披露的ARTEMIS-008研究期中分析结果显示：瑞康立伏妥塔单抗在复发性小细胞肺癌患者中展现出具有统计学意义和临床意义的OS改善. |
| 2026-09-13 | GlaxoSmithKline | Results Ris-Rez reduced risk of death by 54% versus topotecan in patients with relapsed small cell lung cancer in China gsk.com ↗
Patients receiving Ris-Rez lived a median of 18.5 months (n=230) compared with 10.3 months for those receiving topotecan (n=231). |
| 2026-09-07 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Regulatory BIOLOGICS LICENSE APPLICATION OF RISVUTATUG REZETCAN (HS-20093) FOR INJECTION FOR SMALL CELL LUNG CANCER ACCEPTED BY THE NMPA hspharm.com ↗ |
| 2026-09-02 | Hansoh BioMedical R&D Company | Regulatory 翰森制药注射用HS-20093治疗小细胞肺癌的上市许可申请获国家药品监督管理局正式受理 hansoh.cn ↗
2026年9月2日，翰森制药集团有限公司（翰森制药，03692. HK）宣布，公司自主研发的注射用HS-20093（Risvutatug Rezetecan）用于治疗既往含铂治疗失败的小细胞肺癌（SCLC）成人患者的上市许可申请获中国国家药品监督管理局(NMPA)受理，受理号为CXSS2600134. |
| 2026-07-28 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Results HANSOH PHARMA ANNOUNCES ARTEMIS-011 PHASE 3 TRIAL OF RISVUTATUG REZETECAN (HS-20093) MET PRIMARY ENDPOINT OF IRC-ASSESSED PFS IN OSTEOSARCOMA hspharm.com ↗
Compared with chemotherapy, Ris-Rez demonstrated a statistically significant and clinically meaningful improvement in IRC-assessed PFS. |
| 2026-07-28 | Hansoh BioMedical R&D Company | Results 翰森制药 | B7-H3 ADC Risvutatug Rezetecan（HS-20093）骨肉瘤III期临床ARTEMIS-011达到IRC-PFS主要终点 hansoh.cn ↗
与化疗相比，Risvutatug Rezetecan 在 IRC 评估的 PFS 方面显示出具有统计学显著性和临床意义的改善. |
| 2026-07-10 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Results HANSOH PHARMA ANNOUNCES ARTEMIS-008 TRIAL OF RISVUTATUG REZETECAN (HS-20093) MET ITS PRIMARY ENDPOINT OF OVERALL SURVIVAL IN SMALL CELL LUNG CANCER hspharm.com ↗
At a pre-specified interim analysis, Ris-Rez provided statistically significant and clinically meaningful OS improvements compared with topotecan. |
| 2026-07-10 | Hansoh BioMedical R&D Company | Results 翰森制药 | HS-20093（B7-H3 ADC）小细胞肺癌Ⅲ期临床研究ARTEMIS-008达到OS主要终点 hansoh.cn ↗
在预设的期中分析中，与托泊替康相比，Risvutatug Rezetecan在OS方面显示出具有统计学意义和临床意义的改善. |
| 2026-07-10 | GlaxoSmithKline | Results GSK’s licensor Hansoh Pharma announces positive phase III results for Ris-Rez in China patient population gsk.com ↗
In the trial, conducted in patients in China, Ris-Rez demonstrated statistically significant and clinically meaningful improvements in OS compared with the standard of care, topotecan. |
| 2026-06-18 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Results ESMO TAT ASIA 2026 | HANSOH PHARMA PRESENTS PHASE 2 DATA OF RISVUTATUG REZETECAN (RIS-REZ) IN RELAPSED OR REFRACTORY SARCOMAS hspharm.com ↗
At ESMO TAT Asia 2026, long-term follow-up results were presented for adult and adolescent (12-<18 years) patients with osteosarcoma, as well as for adult patients with soft tissue sarcoma (STS) from this study. |
| 2026-06-18 | Hansoh BioMedical R&D Company | Results ESMO TAT ASIA 2026 | 翰森制药公布Risvutatug Rezetecan（B7-H3 ADC）用于复发或难治性肉瘤治疗的Ⅱ期研究数据 hansoh.cn ↗ |
| 2026-04-20 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Results AACR 2026 | HANSOH PHARMA PRESENTED PHASE 1 RESULTS OF RISVUTATUG REZETECAN PLUS ADEBRELIMAB IN NON-SQUAMOUS NSCLC WITHOUT ACTIONABLE GENOMIC ALTERATIONS hspharm.com ↗
At AACR 2026, data from an expansion cohort of the phase 1 ARTEMIS-101 study evaluating risvutatug rezetecan plus adebrelimab in patients with previously treated nsq-NSCLC without AGAs were presented as an oral presentation. |
| 2026-04-20 | Hansoh BioMedical R&D Company | Results AACR 2026 | 翰森制药Risvutatug Rezetecan（B7-H3 ADC）联合阿得贝利单抗治疗驱动基因阴性的非鳞状NSCLC的Ⅰ期研究结果发布 hansoh.cn ↗
Risvutatug rezetecan联合阿得贝利单抗在既往经治的驱动基因阴性非鳞状非小细胞肺癌患者中确认的客观缓解率达47. 1%，中位无进展生存期为14. 0个月（32. 4%事件发生率），且安全性总体可控. |
| 2026-03-23 | GlaxoSmithKline | Regulatory GSK’s B7-H3-targeted antibody-drug conjugate, risvutatug rezetecan, granted Orphan Drug Designation for small-cell lung cancer in Japan gsk.com ↗
GSK plc (LSE/NYSE: GSK) today announced that risvutatug rezetecan (or Ris-Rez, for short), a B7-H3-targeted antibody-drug conjugate (ADC), has received Orphan Drug Designation (ODD) from Japan’s Ministry of Health, Labour and Welfare for the treatment of small-cell lung cancer (SCLC). |
| 2026-03-06 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Results CANCER CELL PUBLISHES PHASE 1 LUNG CANCER RESULTS OF RISVUTATUG REZETECAN hspharm.com ↗
In ES-SCLC (N=65), the cORR was 52.3% in a population in which approximately 60% had received ≥2 prior lines of therapy; median duration of response (DoR) was 7.1 months, median progression-free survival (PFS) was 6.2 months and median overall survival (OS) was 13.0 months. |
| 2026-03-06 | Hansoh BioMedical R&D Company | Results 翰森制药丨Cancer Cell 发表B7-H3靶向ADC Risvutatug Rezetecan Ia/b期肺癌研究数据 hansoh.cn ↗
65例经治ES-SCLC患者中约60%既往接受过≥2线治疗，cORR为52. 3%，中位缓解持续时间（DoR）为7. 1个月，中位无进展生存期（PFS）为6. 2个月，中位总生存期（OS）为13. 0个月. |
| 2026-02-28 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Results ASCO GU 2026 | HANSOH PHARMA PRESENTED PHASE 2 DATA OF RISVUTATUG REZETECAN IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER hspharm.com ↗
Risvutatug rezetecan showed anti-tumor activity with a generally manageable safety profile in patients with metastatic castration-resistant prostate cancer (mCRPC) who had progressed after prior novel hormonal agents. |
| 2026-02-27 | Hansoh BioMedical R&D Company | Results ASCO GU 2026 | 翰森制药Risvutatug Rezetecan(B7-H3 ADC)治疗转移性去势抵抗性前列腺癌 (mCRPC)II期临床数据发布 hansoh.cn ↗
Risvutatug Rezetecan 在既往接受过紫杉烷类治疗和未接受过紫杉烷类治疗的转移性去势抵抗性前列腺癌患者中，均显示出令人鼓舞的抗肿瘤活性. |
| 2025-12-17 | Hansoh BioMedical R&D Company | Results ESMO ASIA | 翰森制药Risvutatug Rezetecan（ HS-20093）治疗NSCLC的Ⅰ期研究结果亮相 hansoh.cn ↗
该亚组中，8. 0 mg/kg 组经确认客观缓解率（cORR）达33. 3%，中位无进展生存期（mPFS）7. 0 个月，中位总生存期（mOS）尚未达到；10. 0 mg/kg 组 cORR 为 10. 7%，mPFS 4. 1 个月，mOS 17. 5 个月. |
| 2025-12-10 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Results ESMO ASIA | HANSOH PHARMA ANNOUNCES MINI ORAL PRESENTATION OF PHASE 1 STUDY OF RISVUTATUG REZETECAN (HS-20093, A B7-H3-TARGETED ADC) IN PATIENTS WITH NON-SMALL CELL LUNG CANCER (NSCLC) hspharm.com ↗
Risvutatug rezetecan administered at 8.0 and 10.0 mg/kg every 3 weeks showed encouraging anti-tumour activity in patients with locally-advanced or metastatic Non-Small Cell Lung Cancer (NSCLC), especially in patients with non-squamous NSCLC without actionable genomic alterations(AGAs). |
| 2025-12-10 | GlaxoSmithKline | Regulatory GSK’227, a B7-H3-targeted antibody-drug conjugate, granted Orphan Drug Designation in small-cell lung cancer by the US FDA gsk.com ↗
GSK plc (LSE/NYSE: GSK) today announced that its B7-H3-targeted antibody-drug conjugate GSK’227, now referred to by its International Nonproprietary Name, risvutatug rezetecan, has received Orphan Drug Designation (ODD) from the US Food and Drug Administration (FDA) for the treatment of small-cell lung cancer (SCLC). |
| 2025-10-28 | GlaxoSmithKline | Regulatory GSK’s B7-H3-targeted antibody-drug conjugate, GSK’227, receives Orphan Drug Designation in the EU gsk.com ↗
This ODD recognises the potential of GSK’227 to address a significant unmet need for ES-SCLC, an aggressive type of NEC with poor outcomes and limited treatment options. |
| 2025-10-20 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Results ESMO 2025 | HANSOH PHARMA ANNOUNCES PROFFERED PAPER PRESENTATION OF PHASE 2 STUDY ON HS-20093 (B7-H3-TARGETED ADC) IN RELAPSED OR REFRACTORY SARCOMAS hspharm.com ↗
HS-20093 administered at 12.0 mg/kg every 3 weeks showed a manageable safety profile in patients with R/R osteosarcoma and STS, and no new safety signal was identified. |
| 2025-10-20 | Hansoh BioMedical R&D Company | Results ESMO | 翰森制药HS-20093(B7-H3 ADC)用于复发或难治性肉瘤治疗的II期研究结果入选优选口头报告 hansoh.cn ↗
在骨肉瘤患者中，与8mg/kg每3周1次剂量相比，12mg/kg每3周1次剂量的HS-20093展现了更好的生存获益趋势. |
| 2025-04-17 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Regulatory HANSOH PHARMA ANNOUNCES NMPA HAS GRANTED BREAKTHROUGH-THERAPY-DESIGNATED DRUG FOR B7-H3-TARGETED ANTIBODY-DRUG CONJUGATE HS-20093 FOR NSNSCLC hspharm.com ↗ |
| 2025-02-25 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Regulatory HANSOH PHARMA ANNOUNCES NMPA HAS GRANTED BREAKTHROUGH-THERAPY-DESIGNATED DRUG FOR B7-H3-TARGETED ANTIBODY-DRUG CONJUGATE HS-20093 FOR OSTEOSARCOMA hspharm.com ↗
HS-20093 for injection has obtained approval to be included as Breakthrough-Therapy-Designated Drug by the National Medical Products Administration (NMPA) of China |
| 2025-01-07 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Regulatory HS-20093, B7-H3-TARGETED ANTIBODY-DRUG CONJUGATE, RECEIVES US FDA BREAKTHROUGH THERAPY DESIGNATION IN LATE-LINE RELAPSED OR REFRACTORY OSTEOSARCOMA hspharm.com ↗
HS-20093/GSK’227 receives FDA BTD in late-line relapsed or refractory osteosarcoma based on Hansoh’s promising early data. |
| 2025-01-07 | Hansoh BioMedical R&D Company | Regulatory 翰森制药HS-20093再获FDA突破性疗法认定，用于后线复发或难治性骨肉瘤治疗 hansoh.cn ↗ |
| 2025-01-07 | GlaxoSmithKline | Regulatory GSK’s B7-H3-targeted antibody-drug conjugate, GSK’227, receives US FDA Breakthrough Therapy Designation in late-line relapsed or refractory osteosarcoma gsk.com ↗ |
| 2024-12-16 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Regulatory HS-20093, B7-H3-TARGETED ANTIBODY-DRUG CONJUGATE, RECEIVES EMA PRIORITY MEDICINES DESIGNATION. hspharm.com ↗
HS-20093/GSK’227 receives EMA Priority Medicines (PRIME) Designation in relapsed extensive-stage small-cell lung cancer (“ES-SCLC”) . |
| 2024-12-16 | GlaxoSmithKline | Regulatory GSK’s B7-H3-targeted antibody-drug conjugate, GSK’227, receives EMA Priority Medicines (PRIME) Designation in relapsed extensive-stage small-cell lung cancer gsk.com ↗
GSK plc (LSE/NYSE: GSK) announced today that the European Medicines Agency (EMA) has granted Priority Medicines (PRIME) Designation for GSK5764227 (GSK’227), its B7-H3-targeted antibody-drug conjugate (ADC) being evaluated for the treatment of patients with relapsed extensive-stage small-cell lung cancer (ES-SCLC). |
| 2024-11-01 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Regulatory HANSOH PHARMA ANNOUNCES NMPA HAS GRANTED BREAKTHROUGH-THERAPY-DESIGNATED DRUGS FOR HS-20093 hspharm.com ↗
HS-20093 for injection has been approved to be included as Breakthrough-Therapy-Designated Drugs by the National Medical Products Administration (NMPA) of China |
| 2024-09-09 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Results HS-20093, AN INVESTIGATIONAL B7-H3 TARGETED ANTIBODY-DRUG CONJUGATE, DEMONSTRATES ENCOURAGING RESULTS IN RELAPSED OR REFRACTORY EXTENSIVE-STAGE SMALL-CELL LUNG CANCER（UPDATES FROM ARTEMIS-001 PHASE I TRIAL AT WCLC 2024） hspharm.com ↗
We are excited about the encouraging results presented at the World Conference on Lung Cancer evaluating HS-20093 in this very difficult to treat patient population. |
| 2024-08-27 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Regulatory HANSOH PHARMA ANNOUNCES US FDA HAS GRANTED BREAKTHROUGH THERAPY DESIGNATION FOR HS-20093 hspharm.com ↗ |
| 2024-08-21 | Hansoh BioMedical R&D Company | Regulatory 翰森制药HS-20093（B7-H3 ADC）获FDA突破性疗法认定 hansoh.cn ↗
2024年8月20日 翰 森 制 药 集 团 有 限 公 司 (以 下 简 称“翰 森 制 药”，03692. HK)宣 布，合 作 方 葛 兰 素 史 克（GSK）就HS-20093 (GSK5764227)获 美 国 食 品 药 品 监 督 管 理 局（FDA）突 破 性 疗 法 认 定，此B7-H3靶 向 抗 体 药 物 偶 联 物（ADC）正 在 评 估 用 于 含 铂 化 疗 期 间 或 之 后 进 展 的（复 发 或 难 治 性）广 泛 期 小 细 胞 肺 癌（ES-SCLC）患 者 治 疗. |
| 2024-08-20 | GlaxoSmithKline | Regulatory GSK receives US FDA Breakthrough Therapy Designation for its B7-H3-targeted antibody-drug conjugate in relapsed or refractory extensive-stage small-cell lung cancer gsk.com ↗ |
| 2024-06-07 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Results 2024 ASCO ANNUAL MEETING | FIVE INNOVATIVE STUDIES SPONSORED BY HANSOH PHARMA PRESENTED AT GRAND ACADEMIC EVENT hspharm.com ↗
in the 12.0 mg/kg group, the ORR was 17.4% |
| 2023-06-05 | Hansoh BioMedical R&D Company | Results 2023 ASCO | 翰森制药B7-H3 ADC、c-MET TKI等研究成果亮相，临床潜力获国际权威认可 hansoh.cn ↗
根据研究者按照RECIST 1. 1标准评估的结果，客观缓解率（ORR）为30. 0%，疾病控制率为86. 0%，中位无进展生存期（mPFS）为5. 4个月. |
| 2021-07-15 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Regulatory HANSOH PHARMA'S IND APPLICATION FOR TWO CLASS 1 BIOLOGICAL INNOVATIVE DRUGS ACCEPTED hspharm.com ↗
Recently, the investigational new drug （IND） application for HS-20089 （for injection） and HS-20093 （for injection）， two new Class 1 therapeutic biological products independently developed by Shanghai Hansoh BioMedical Co., Ltd. under Hansoh Pharma （3692.HK）， was accepted and publicized by the National Medical Products Administration （NMPA）。 |
All press releases naming this drug 44 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 24 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HS-20093 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06052423 ↗ |
| Modality | Other / unclassified | “fully humanized IgG1 antibody-drug conjugate (ADC)” NCT05830123 ↗ |
| Route | Intravenous | “Intravenous (IV) administration of HS-20093 Q3W” NCT05276609 ↗ |